Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cytomegalovirus-encoded immediate early 1 protein perturbs neural progenitor proliferation via interfering with host PML-DISC1 interaction.

The Journal of biological chemistry·2026
Same author

DISC1-PML protein interaction for congenital CMV infection-induced cortical neural progenitor deficit: perturbance of host signaling via viral IE1.

bioRxiv : the preprint server for biology·2025
Same author

Withdrawal: RNA Silencing Identifies PDE4D5 as the Functionally Relevant cAMP Phosphodiesterase Interacting with βArrestin to Control the Protein Kinase A/AKAP79-mediated Switching of the β<sub>2</sub>-Adrenergic Receptor to Activation of ERK in HEK293B2 Cells.

The Journal of biological chemistry·2025
Same author

Activation of Phosphodiesterase 3A: New Hope for Cardioprotection.

Circulation·2022
Same author

Correction for Bjørgo et al., "Cross Talk between Phosphatidylinositol 3-Kinase and Cyclic AMP (cAMP)-Protein Kinase A Signaling Pathways at the Level of a Protein Kinase B/β-Arrestin/cAMP Phosphodiesterase 4 Complex".

Molecular and cellular biology·2022
Same author

Regulation of sensorimotor gating via Disc1/Huntingtin-mediated Bdnf transport in the cortico-striatal circuit.

Molecular psychiatry·2022

Related Experiment Video

Updated: Jun 24, 2026

Monitoring GPCR-&#946;-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
08:21

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Published on: June 28, 2019

Arrestin times for developing antipsychotics and beta-blockers.

Miles D Houslay1

  • 1Neuroscience and Molecular Pharmacology, Wolfson and Davidson Buildings, University of Glasgow, Glasgow G12 8QQ, Scotland, UK. m.houslay@bio.gla.ac.uk

Science Signaling
|April 16, 2009
PubMed
Summary

Beta-arrestins, once seen as negative regulators, are emerging as key therapeutic targets. Their interaction with G protein-coupled receptors (GPCRs) offers new avenues for treating conditions like schizophrenia and heart failure.

More Related Videos

Parallel Interrogation of &#946;-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay
09:03

Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay

Published on: March 10, 2020

Dual Extracellular Recordings in the Mouse Hippocampus and Prefrontal Cortex
04:44

Dual Extracellular Recordings in the Mouse Hippocampus and Prefrontal Cortex

Published on: February 16, 2024

Related Experiment Videos

Last Updated: Jun 24, 2026

Monitoring GPCR-&#946;-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
08:21

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Published on: June 28, 2019

Parallel Interrogation of &#946;-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay
09:03

Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay

Published on: March 10, 2020

Dual Extracellular Recordings in the Mouse Hippocampus and Prefrontal Cortex
04:44

Dual Extracellular Recordings in the Mouse Hippocampus and Prefrontal Cortex

Published on: February 16, 2024

Area of Science:

  • Molecular pharmacology
  • Cellular signaling
  • Drug discovery

Background:

  • G protein-coupled receptors (GPCRs) are the largest protein family in the human genome.
  • GPCRs mediate cellular responses by interacting with G proteins and beta-arrestins.
  • Beta-arrestins were traditionally considered negative regulators of GPCR signaling.

Purpose of the Study:

  • To explore the potential of beta-arrestins as therapeutic targets.
  • To investigate the novel roles of beta-arrestins in GPCR signaling.
  • To highlight new therapeutic strategies based on GPCR-beta-arrestin interactions.

Main Methods:

  • Analysis of GPCR and beta-arrestin interactions.
  • Review of existing therapeutic interventions targeting GPCRs.
  • Examination of drug actions on GPCR-beta-arrestin pathways.

Main Results:

  • Certain antipsychotics inhibit dopamine D2 receptor engagement with beta-arrestin 2, impacting glycogen synthase kinase 3.
  • Beta-blockers like carvedilol promote extracellular signal-regulated kinase activation via beta-arrestin.
  • Beta-arrestins can distinguish between different GPCR types and conformational states.

Conclusions:

  • Beta-arrestins are not merely negative regulators but active participants in GPCR signaling.
  • Targeting beta-arrestin interactions with GPCRs presents novel therapeutic opportunities.
  • Understanding beta-arrestin function can lead to the development of new treatments for neurological and cardiovascular diseases.